FrancophonIA/ELRC3.0 huggingface dataset:
English: Questions and answers on the suspension of the marketing authorisations for Octagam (human normal immunoglobulin 5% and 10%) EMA/588737/2010 rev.1
Estonian: Octagami (inimese normaalimmunoglobuliin 5% ja 10%) müügilubade peatamise teave EMA/588737/2010 red.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that all marketing authorisations for the medicine be suspended throughout the European Union (EU) and that Octagam currently on the market be recalled.
Estonian: Euroopa Ravimiameti inimravimite komitee soovitas peatada kõik Octagami müügiload kogu Euroopa Liidus ja võtta turustatav ravim tagasi.
English: Questions and answers on the suspension of the marketing authorisations for Octagam (human normal immunoglobulin 5% and 10%)
Estonian: Octagami (inimese normaalimmunoglobuliin 5% ja 10%) müügilubade peatamise teave
English: This follows an unexpectedly high number of reports of serious thromboembolic events (problems due to the formation of blood clots in the blood vessels) in patients taking the medicine.
Estonian: Sellele eelnes ebatavaliselt palju teateid rasketest tromboemboolianähtudest (trombide ehk soonesiseste verehüüvete tekkest põhjustatud probleemid) ravimit võtvatel patsientidel.
English: The CHMP reviewed the reported thromboembolic events and looked at evidence related to the medicine's safety.
Estonian: Inimravimite komitee vaatas läbi teatatud tromboemboolianähtude andmed ja tutvus ravimi ohutusandmetega.
English: The CHMP therefore recommended that, because of the safety concerns with Octagam, the marketing authorisations for the medicine be suspended in the EU.
Estonian: Komitee soovitas Octagami ebakindla ohutuse tõttu peatada ravimi müügiload Euroopa Liidus.
English: Its effect may improve further for up to six months.
Estonian: Toime võib tugevneda veelgi kuni 6 kuu vältel.
English: It is available as tablets (10, 15 and 20 mg).
Estonian: Seda turustatakse tablettidena (10, 15 ja 20 mg).
English: EMA/CHMP/328573/2014 EMEA/H/C/001227
Estonian: EMA/265372/2014 EMEA/H/C/001227
English: The medicine usually starts to have an effect after four to six weeks.
Estonian: Ravimi toime ilmneb tavaliselt 4-6 nädala pärast.
English: The full EPAR for Leflunomide medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Leflunomide medaci kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Leflunomide medac is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Leflunomide medaci võimalikult ohutu kasutamine.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Leflunomide medac on 27 July 2010.
Estonian: Euroopa Komisjon andis Leflunomide medaci müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. juulil 2010.
English: Leflunomide medac EMA/CHMP/328573/2014
Estonian: Leflunomide medac EMA/265372/2014
English: What measures are being taken to ensure the safe and effective use of Leflunomide medac ?
Estonian: Mis meetmed võetakse, et tagada Leflunomide medaci ohutu ja efektiivne kasutamine?
English: Leflunomide medac treatment usually starts with a ‘loading dose' of 100 mg once a day for three days, followed by a maintenance dose.
Estonian: Ravi Leflunomide medaciga alustatakse tavaliselt küllastusannusega 100 mg üks kord ööpäevas kolme päeva jooksul ning seejärel kasutatakse säilitusannust.
English: Leflunomide medac is used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints) or active psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints).
Estonian: Leflunomide medacit kasutatakse aktiivse reumatoidartriidi (liigesepõletikku põhjustav immuunsüsteemi haigus) või aktiivse psoriaatilise artriidi (punetavaid ketendavaid laike nahal ja liigesepõletikku põhjustav haigus) raviks täiskasvanutel.
English: Because Leflunomide medac is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Estonian: Et Leflunomide medac on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: For more information about treatment with Leflunomide medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Leflunomide medaci ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The Committee recommended that Leflunomide medac be given marketing authorisation.
Estonian: Komitee soovitas anda Leflunomide medaci müügiloa.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Leflunomide medac.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Leflunomide medac, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Leflunomide medaci omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: This document is a summary of the European public assessment report (EPAR) for Leflunomide medac.
Estonian: See on ravimi Leflunomide medac Euroopa avaliku hindamisaruande kokkuvõte.
English: This means that Leflunomide medac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Arava.
Estonian: See tähendab, et Leflunomide medac on sarnane võrdlusravimiga Arava, millel juba on Euroopa Liidus müügiluba.
English: The CHMP concluded that, in accordance with EU requirements, Leflunomide medac has been shown to have comparable quality and to be bioequivalent to Arava.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Leflunomide medac võrdväärne kvaliteet ja bioekvivalentsus ravimiga Arava.
English: Therefore, the CHMP's view was that, as for Arava, the benefit outweighs the identified risk.
Estonian: Seetõttu leidis inimravimite komitee, et nagu ka Arava korral, ületab Leflunomide medaci kasulikkus sellega kaasnevad riskid.
English: Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase', which is necessary for the lymphocytes to multiply.
Estonian: Selleks blokeerib leflunomiid ensüümi dihüdroorotaatdehüdrogenaasi, mida on vaja lümfotsüütide paljunemiseks.
English: Leflunomide medac is a medicine that contains the active substance leflunomide.
Estonian: Leflunomide medac on ravim, mis sisaldab toimeainena leflunomiidi.
English: Leflunomide medac leflunomide
Estonian: Leflunomide medac leflunomiid
English: Because Leflunomide medac is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Arava.
Estonian: Et Leflunomide medac on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Leflunomide medaci bioekvivalentsust võrdlusravimiga Arava.
English: Leflunomide medac is a ‘generic medicine'.
Estonian: Leflunomide medac on geneeriline ravim.
English: Why has Leflunomide medac been approved?
Estonian: Miks Leflunomide medac heaks kiideti?
English: It reduces inflammation by reducing the production of immune cells called ‘lymphocytes', which are responsible for inflammation.
Estonian: Toimeaine leevendab põletikku, vähendades põletikku põhjustavate immuunreaktsioonis osalevate rakkude - lümfotsüütide - teket.
English: What is Leflunomide medac?
Estonian: Mis on Leflunomide medac?
English: The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Leflunomide medac, and regularly during treatment.
Estonian: Arst teeb enne Leflunomide medaci määramist ja ravi ajal regulaarselt vereanalüüse patsiendi maksatalitluse ning leukotsüütide (valgeliblede) ja trombotsüütide (vereliistakute) sisalduse kontrollimiseks.
English: Leflunomide medac treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis and psoriatic arthritis.
Estonian: Ravi Leflunomide medaciga peab alustama reumatoidartriidi ja psoriaatilise artriidi ravis kogenud arst ning see peab toimuma tema järelevalve all.
English: Other information about Leflunomide medac:
Estonian: Muu teave Leflunomide medaci kohta
English: How does Leflunomide medac work?
Estonian: Kuidas Leflunomide medac toimib?
English: The active substance in Leflunomide medac, leflunomide, is an immunosuppressant.
Estonian: Leflunomide medacis toimeainena sisalduv leflunomiid on immunosupressant (immuunvastust vähendav aine).
English: What are the benefit and risk of Leflunomide medac?
Estonian: Milles seisneb Leflunomide medaci kasulikkus ja mis riskid ravimiga kaasnevad?
English: What is Leflunomide medac used for?
Estonian: Milleks Leflunomide medacit kasutatakse?
English: How has Leflunomide medac been studied?
Estonian: Kuidas Leflunomide medacit uuriti?
English: How is Leflunomide medac used?
Estonian: Kuidas Leflunomide medacit kasutatakse?
English: 3 x 28 tablets
Estonian: 3 x 28 tabletti
English: (Invented) name Strength Pharmaceutical form
Estonian: Tugevus Ravimvorm Manustamistee
English: The following information is intended for medical or healthcare professionals only:
Estonian: Järgmine teave on ainult meditsiinipersonalile või tervishoiutöötajale:
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 September 2015
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 14. september 2015
English: OTHER SPECIAL WARNING(S), IF NECESSARY cytotoxic
Estonian: TEISED ERIHOIATUSED (VAJADUSEL) tsütotoksiline
English: * Definition of frequency terms: Very common - ≥ 10 %; Common - > 5 % and < 10 %.
Estonian: * Esinemissageduste definitsioon: Väga sage - ≥ 10 %; Sage - > 5 % ja < 10 %.
English: The use of Pemetrexed Lilly should be avoided during pregnancy.
Estonian: Pemetrexed Lilly kasutamist tuleb raseduse ajal vältida.
English: Pharmacotherapeutic group: Antineoplastic agents, antimetabolites, folic acid analogues, ATC code: L01BA04
Estonian: Farmakoterapeutiline rühm: kasvajavastased ained, antimetaboliidid, foolhappe analoogid, ATC-kood: L01BA04
English: Do not use Pemetrexed Lilly - if you are allergic (hypersensitive) to pemetrexed or any of the other ingredients of this medicine (listed in section 6).
Estonian: Ärge kasutage Pemetrexed Lilly't - kui te olete pemetrekseedi või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2 °C to 8 °C.
Estonian: Kui ravimit ei kasutata kohe, on kõlblikkusaeg ja säilitamistingimused kasutaja vastutusel, ega tohiks ületada 24 tundi temperatuuril 2°C kuni 8°C.
English: Safety was assessed for patients who were randomised to receive pemetrexed (N = 800).
Estonian: Ohutust hinnati patsientidel, kes randomiseeriti saama pemetrekseedi (N=800).
English: In vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter.
Estonian: In vitro uuringud viitavad, et pemetrekseed eritub aktiivselt OAT3 abil (orgaaniline anioonide transportija).
English: Based on the planned date of your infusion of Pemetrexed Lilly and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them.
Estonian: Olenevalt teie plaanilisest Pemetrexed Lilly infusiooni päevast ja/või teie neerufunktsiooni seisundist, annab arst teile nõu, missuguseid ravimeid ja millal te neid tohite kasutada.
English: Creatinine clearance should be ≥ 45 mL/min.
Estonian: Kreatiniini kliirens peab olema ≥ 45 ml/min.
English: Lilly France Zone Industrielle 2 Rue du Colonel Lilly 67640 Fegersheim France
Estonian: Lilly France Zone Industrielle 2 Rue du Colonel Lilly 67640 Fegersheim Prantsusmaa
English: Not known: frequency cannot be estimated from the available data Lower limb swelling with pain and redness Increased urine output
Estonian: Teadmata: esinemissagedust ei saa hinnata olemasolevate andmete alusel Alajäseme turse koos valu ja punetusega Uriinierituse suurenemine
English: Vitamin B12 and folic acid are given to you to reduce the possible toxic effects of the anticancer treatment.
Estonian: B12-vitamiini2 ja foolhapet antakse teile selleks, et vähendada vähivastase ravi võimalikke toksilisi toimeid.
English: Frequency estimate: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000) and not known (cannot be estimated from available data).
Estonian: Esinemissagedus: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 1/10 000) ja teadmata (ei ole võimalik hinnata olemasolevate andmete alusel).
English: ** In the pemetrexed/cisplatin arm, randomized and treated (N = 225) and fully supplemented (N = 167)
Estonian: ** Pemetrekseedi /tsisplatiini harus, randomiseeritud ja ravitud (N = 225) ning lisandiga (N = 167)
English: Do not use this medicine after the expiry date which is stated on the label and carton.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud karbil.
English: Non-inferiority p-value (HR) Progression free survival (months) Median
Estonian: Mittehalvemuse p-väärtus (HR) Progressioonivaba elulemus (kuud) Mediaan
English: Instructions for use, handling and disposal.
Estonian: Kasutamis-, käsitlemis-ja hävitamisjuhend
English: DATE OF REVISION OF THE TEXT Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Estonian: TEKSTI LÄBIVAATAMISE KUUPÄEV Täpne informatsioon selle ravimi kohta on kättesaadav Euroopa Ravimiameti (EMA) kodulehel http://www.ema.europa.eu
English: Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pemetrexed Lilly.
Estonian: Enne iga infusiooni tehakse teile vereanalüüs, mille järgi hinnatakse, kas teil on piisavalt hea neeru- ja maksafunktsioon, ning vaadatakse, kas teil on piisaval hulgal vererakke, mis lubab Pemetrexed Lilly't manustada.
English: Immune-mediated haemolytic anaemia (antibody-mediated destruction of red blood cells) Hepatitis (inflammation of the liver)
Estonian: Immuunne hemolüütiline aneemia (antikehadest tingitud vere punaliblede hävinemine) Hepatiit (maksapõletik)
English: Calculate the dose and the number of Pemetrexed Lilly vials needed.
Estonian: Arvutage välja annus ja selleks vajalik Pemetrexed Lilly viaalide arv.
English: Other medicines and Pemetrexed Lilly
Estonian: Muud ravimid ja Pemetrexed Lilly
English: Men are advised not to father a child during and up to 6 months following treatment with Pemetrexed Lilly and should therefore use effective contraception during treatment with Pemetrexed Lilly and for up to 6 months afterwards.
Estonian: Meestel ei ole soovitatav ravi ajal ja kuni 6 kuu jooksul pärast ravi Pemetrexed Lilly'ga last viljastada ning nad peavad seetõttu ravi ajal ja kuni 6 kuu jooksul pärast ravi Pemetrexed Lilly'ga kasutama efektiivset kontratseptsiooni.
English: The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N = 519), and compared to patients who received > 6 cycles of pemetrexed (N = 281).
Estonian: Kõrvaltoimete esinemissagedust hinnati patsientidel, kes said ≤ 6 tsüklit pemetrekseedi säilituraviks (N=519), ning seda võrreldi patsientidega, kes said > 6 tsüklit pemetrekseedi (N=281).
English: Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be ≤ 3 times upper limit of normal.
Estonian: Alkaalne fosfataas, aspartaataminotransferaas (ASAT või SGOT) ja alaniinaminotransferaas (ALAT või SGPT) peavad olema ≤ 3 korda normi ülemisest piirist.
English: Pemetrexed Lilly is a medicine used in the treatment of cancer.
Estonian: Pemetrexed Lilly on ravim, mida kasutatakse vähktõve raviks.
English: Common Pain Edema Renal Disorders Common Renal disorders**** Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacectic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.
Estonian: Lühendid: ALAT = alaniinaminotransferaas; ASAT = aspartaataminotransferaas; CTCAE = kõrvaltoime üldised terminoloogilised kriteeriumid (Common Terminology Criteria for Adverse Event); NCI = Riiklik Vähiinstituut (National Cancer Institute); SGOT = seerumi glutamaat-oksaloatsetaat-aminotransferaas; SGPT = seerumi glutamaat-püruvaat-aminotransferaas.
English: Upon recovery patients should be retreated using the guidelines in Tables 1, 2 and 3, which are applicable for Pemetrexed Lilly used as a single agent or in combination with cisplatin.
Estonian: Pärast taastumist tuleb patsiendil ravi taasalustada vastavalt tabelites 1, 2 ja 3 esitatud juhenditele, mis kehtivad Pemetrexed Lilly monoteraapia või kombinatsioonis tsisplatiiniga kasutamise kohta.
English: Common (may affect up to 1 in 10 people) Allergic reaction: skin rash / burning or prickling sensation Infection including sepsis
Estonian: Sage (võib esineda kuni 1-l inimesel 10st) Allergiline reaktsioon: nahalööve / kipitus- või kihelustunne Infektsioon, sh sepsis
English: The other ingredients are mannitol (E421), hydrochloric acid and sodium hydroxide (see section 2 “Pemetrexed Lilly contains sodium”)
Estonian: Abiained on mannitool (E421), soolhape ja naatriumhüdroksiid (vt lõik 2 „Pemetrexed Lilly sisaldab naatriumi“).
English: Alkaline phosphatase, AST and ALT ≤ 5 times upper limit of normal is acceptable if liver has tumour involvement.
Estonian: Alkaalse fosfataasi, ASAT ja ALAT väärtusi ≤ 5 korda normi ülemisest piirist võib aktsepteerida sel juhul, kui tuumor on metastaseerunud maksa.
English: At the time of this final survival analysis, 28.7 % of patients were alive or lost to follow up on the pemetrexed arm versus 21.7 % on the placebo arm.
Estonian: Elulemuse lõpliku analüüsi ajal oli 28,7% pemetrekseedi-grupi patsientidest elus või jäid mingil põhjusel jälgimise ajal uuringust välja, võrreldes 21,7% platseebogrupi patsientidega.
English: A hospital pharmacist, nurse or doctor will have mixed the Pemetrexed Lilly powder with 9 mg/mL (0.9 %) sodium chloride solution for injection before it is given to you.
Estonian: Haigla apteeker, meditsiiniõde või arst on Pemetrexed Lilly pulbri seganud 9 mg/ml (0,9 %) naatriumkloriidi süstelahusega, enne kui see teile manustatakse.
English: Rare (may affect up to 1 in 1,000 people)
Estonian: Harv (võib esineda kuni 1-l inimesel 1000st)
English: Manufacturer Lilly France S.A.S.
Estonian: Lilly France S.A.S.
English: Pemetrexed Lilly should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Estonian: Pemetrexed Lilly tuleb manustada intravenoosse infusioonina 10 minuti jooksul iga 21-päevase tsükli esimesel päeval.
English: Reconstituted and infusion solution: The product should be used immediately.
Estonian: Lahustatud ravim ja infusioonilahus: Ravimit tuleb kasutada kohe pärast lahustamist.
English: Chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at refrigerated temperature.
Estonian: Pemetrekseedi valmistatud lahuse ja infusioonilahuste keemilisfüüsikaline stabiilsust on tõestatud 24 tunni jooksul külmkapitemperatuuril.
English: 3528 BJ Utrecht
Estonian: Papendorpseweg 83 3528 BJ Utrecht Holland
English: What you need to know before you use Pemetrexed Lilly
Estonian: Mida on vaja teada enne Pemetrexed Lilly kasutamist
English: A total of 169 patients (47.1 %) completed ≥ 6 cycles maintenance treatment with pemetrexed, representing at least 10 total cycles of pemetrexed.
Estonian: Kokku lõpetas ≥ 6 tsüklilise säilitusravi pemetrekseediga 169 patsienti (47,1%), mis kokku moodustas vähemalt 10 tsüklit pemetrekseediga.
English: Pemetrexed Lilly can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy.
Estonian: Pemetrexed Lilly't võib teile määrata, kui teie kopsuvähk on kaugelearenenud staadiumis, kui teie haigus on ravile allunud või on jäänud pärast esmast keemiaravi suuremalt jaolt muutumatuks.
English: Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Pemetrexed Lilly has finished.
Estonian: Ka tsisplatiini manustatakse veeniinfusioonina, ning seda tehakse ligikaudu 30 minutit pärast Pemetrexed Lilly infusiooni lõppu.
English: Pemetrexed total systemic clearance is 91.8 mL/min and the elimination half-life from plasma is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
Estonian: Pemetrekseedi totaalne süsteemne kliirens on 91,8 mL/min ja plasma eliminatsiooni poolväärtusaeg normaalse neerufunktsiooniga (kreatiniini kliirens 90 mL/min) patsientidel - 3,5 tundi.
English: The percentage of patients that received post study treatment was 64.3 % for pemetrexed and 71.7 % for placebo.
Estonian: Patsientide protsent, kes said uuringu järgselt ravi, oli pemetrekseedi -grupis 64,3% ja platseebo grupis
English: Your doctor will discuss with you the potential risk of taking Pemetrexed Lilly during pregnancy.
Estonian: Arst räägib teile raseduse ajal Pemetrexed Lilly kasutamisega kaasnevatest võimalikest ohtudest.
English: The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing pemetrexed in all subsets of the paediatric population in the granted indications (see section 4.2 for information on paediatric use).
Estonian: Euroopa Ravimiamet ei kohusta esitama pemetrekseediga läbi viidud uuringute tulemusi laste kõikide alarühmade kohta kinnitatud näidustuste korral (vt lõik 4.2).
English: The high intra-individual variability of the coagulation status during diseases and the possibility of interaction between oral anticoagulants and anticancer chemotherapy require increased frequency of INR (International Normalised Ratio) monitoring, if it is decided to treat the patient with oral anticoagulants.
Estonian: Kuna verehüübivus võib inimesel haiguste ajal suurel määral kõikuda ning suukaudsete antikoagulantide ja vähivastaste kemoterapeutikumide vahel võib esineda koostoime, siis tuleb INRi (International Normalised Ratio/rahvusvaheline normaliseeritud suhtarv) sagedamini jälgida, kui patsienti on otsustatud samaaegselt suukaudsete antikoagulantidega ravida.
English: 75 % of previous dose (both Pemetrexed Lilly and cisplatin)
Estonian: 75 % eelmisest annusest (nii Pemetrexed Lilly kui tsisplatiin).
English: What Pemetrexed Lilly is and what it is used for
Estonian: Mis ravim on Pemetrexed Lilly ja milleks seda kasutatakse
English: Sodium hydroxide (for pH adjustment)
Estonian: Soolhape (pH korrigeerimiseks) Naatriumhüdroksiid (pH korrigeerimiseks)